Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.30 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511776 | 0.89 | GRM2 (0.33) | F2RL3CTSSGRM2 | |
| SCHEMBL8510140 | 0.88 | GRM2 (0.37) | F2RL3CTSSGRM2 | |
| SCHEMBL8511915 | 0.87 | F2RL3 (0.39) | F2RL3CTSSGRM2FFAR1METAP2 | |
| SCHEMBL8511926 | 0.87 | GRM2 (0.32) | F2RL3CTSSGRM2 | |
| SCHEMBL8510107 | 0.86 | GRM2 (0.34) | GRM2GRM5FFAR1PDCD1CD274 | |
| SCHEMBL9604223 | 0.85 | GRM2 (0.36) | CTSSGRM2PDCD1CD274 | |
| SCHEMBL8511759 | 0.84 | GRM2 (0.37) | F2RL3CTSSGRM2CTSK | |
| SCHEMBL8512575 | 0.83 | CTSS (0.42) | F2RL3CTSSGRM2CTSK | |
| SCHEMBL8512353 | 0.81 | GRM2 (0.38) | GRM2FFAR1PTGER1 | |
| SCHEMBL9604222 | 0.81 | GRM2 (0.42) | GRM2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | claimed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | claimed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785481-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135977-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | F2RL3 2251/4885CTSS 4520/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.